Department of Pharmacy, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050000, P. R. China.
Department of Pharmaceutical Analysis, School of Pharmacy, Hebei Medical University, Shijiazhuang, Hebei, 050017, P. R. China.
PLoS One. 2023 Aug 9;18(8):e0289121. doi: 10.1371/journal.pone.0289121. eCollection 2023.
Radix Scutellaria-Licorice drug pair (RSLDP), a frequently used herbal pair with the effect of clearing heat and detoxifying, is the commonly employed drug pair in TCM prescriptions for the treatment of COVID-19. Until now, the metabolism feature and anti-COVID-19 mechanism of RSLDP have not been fully elucidated. In this study, a sensitive and rapid method was developed for the separation and identification of the absorbed constituents of RSLDP in the rat plasma by UHPLC-QTOF-MS. Additionally, we optimized the conventional methodologies of network pharmacology and proposed a new concept called target network pharmacology (T-NP). It used the absorbed constituents and the corresponding targets to generate a compound-target network, and compared to conventional network pharmacology, it could reduce false-positive results. A total of 85 absorbed constituents were identified or tentatively characterized in dosed plasma, including 32 components in the group of Radix Scutellaria, 27 components in the group of Licorice, and 65 components in the group of RSLDP. The results showed that the compatibility of Radix Scutellaria and Licorice increased the number of components in vivo. We found that 106 potential targets among the 61 active compounds in RSLDP were related to COVID-19. And 12 targets (STAT3, AKT1, EGFR, HSP9AA1, MAPK3, JUN, IL6, VEGFA, TNF, IL2, RELA, and STAT1) could be core targets for RSLDP in treating COVID-19. Results from these targets indicate that RSLDP treatment of COVID-19 mainly involves response to chemical stress, response to oxygenates, positive regulation of cytokines, PI3K-Akt signaling pathway, AGE-RAGE signaling pathway for diabetic complications, virus-related pathways such as novel coronavirus and human cytomegalovirus infection, inflammatory immune-related pathways, and so on. The metabolism feature of RSLDP in vivo was systematically uncovered. The combined use of the T-NP method could discover potential drug targets and disclose the biological processes of RSLDP, which will clarify the potential mechanisms of RSLDP in the treatment of COVID-19.
黄芩-甘草药对(RSLDP)是一种具有清热解毒作用的常用草药对,是治疗 COVID-19 的中医方剂中常用的药对。到目前为止,RSLDP 的代谢特征和抗 COVID-19 机制尚未完全阐明。在这项研究中,我们开发了一种灵敏、快速的 UHPLC-QTOF-MS 方法,用于分离和鉴定 RSLDP 在大鼠血浆中的吸收成分。此外,我们优化了传统的网络药理学方法,并提出了一个新概念,称为靶标网络药理学(T-NP)。它使用吸收成分和相应的靶标生成一个化合物-靶标网络,与传统的网络药理学相比,它可以减少假阳性结果。在给药后的血浆中,共鉴定或初步鉴定出 85 种吸收成分,其中黄芩组有 32 种成分,甘草组有 27 种成分,RSLDP 组有 65 种成分。结果表明,黄芩和甘草的配伍增加了体内的成分数量。我们发现,RSLDP 中 61 种活性化合物中的 106 个潜在靶标与 COVID-19 相关。并且 12 个靶标(STAT3、AKT1、EGFR、HSP9AA1、MAPK3、JUN、IL6、VEGFA、TNF、IL2、RELA 和 STAT1)可能是 RSLDP 治疗 COVID-19 的核心靶标。这些靶标结果表明,RSLDP 治疗 COVID-19 主要涉及对化学应激的反应、对含氧物的反应、细胞因子的正调节、PI3K-Akt 信号通路、糖尿病并发症的 AGE-RAGE 信号通路、新型冠状病毒和人巨细胞病毒感染等病毒相关途径、炎症免疫相关途径等。系统地揭示了 RSLDP 在体内的代谢特征。联合使用 T-NP 方法可以发现潜在的药物靶标,并揭示 RSLDP 的生物学过程,这将阐明 RSLDP 治疗 COVID-19 的潜在机制。